Marksans Pharma (NSE:MARKSANS) filed its Q1FY27 investor presentation with the exchanges on 12 August 2026, disclosing an all-time high quarterly EBITDA of Rs 213 crore and PAT of Rs 159 crore, alongside completed acquisitions of QliniQ B.V. in the Netherlands and ABCnow GmbH in Germany.
Key Highlights
- Revenue for Q1FY27 rose 35.6% year-on-year to Rs 840.8 crore, from Rs 620 crore in Q1FY26, with UK and Europe contributing Rs 152 crore of the Rs 221 crore incremental gain.
- EBITDA reached an all-time quarterly high of Rs 213 crore, with EBITDA margin expanding 919 basis points year-on-year to 25.3% in Q1FY27.
- PAT grew 173.9% year-on-year to Rs 159.4 crore, supported by EBITDA growth and a lower effective tax rate of 22.8% in the quarter.
- Cash balance crossed Rs 1,000 crore for the first time, closing Q1FY27 at Rs 1,058 crore, with net cash of Rs 1,031 crore despite recent acquisition spend.
About the Company
Marksans Pharma (NSE:MARKSANS, BSE:524404) is a Mumbai-headquartered pharmaceutical manufacturer focused on over-the-counter and prescription generics across the US, UK, Europe, and Australia and New Zealand. Its key operating subsidiaries include Time-Cap Laboratories Inc. in the US, Bell Sons and Co. and Relonchem Ltd in the UK, and Nova Pharmaceuticals Australasia Pty Ltd in Australia.
Announcement in Detail
The Q1FY27 investor presentation, filed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015, shows consolidated revenue of Rs 840.8 crore, gross profit of Rs 497.3 crore at a margin of 59.1%, and EBITDA of Rs 213 crore at 25.3%. Underlying revenue growth, excluding the Rs 44 crore contribution from the newly acquired QliniQ B.V., was 28.5% year-on-year. Operating cash flow stood at Rs 185 crore and free cash flow at Rs 152 crore for the quarter.
UK and Europe reported their highest-ever quarterly revenue of Rs 356 crore, up 74.7% year-on-year, including Rs 44 crore from QliniQ in its first consolidated quarter. US and North America contributed Rs 377 crore, up 15.1% year-on-year. ABCnow GmbH in Germany was acquired and is expected to be consolidated from Q2FY27. A new Canadian entity, Marksans Canada Inc., has been incorporated with initial product approvals received. India Ratings revised the company's outlook to Positive during the quarter.
Impact on Investors
The filing shows a material improvement in profitability metrics compared with Q1FY26, with EBITDA margin expanding by 919 basis points and PAT margin rising from 9.3% to 18.4% of total income. Investors will note that working capital cycle improved to approximately 132 days from approximately 159 days in Q1FY26, and the cash balance of Rs 1,058 crore was achieved after absorbing acquisition expenditure on QliniQ and ABCnow.
Shareholders will observe that the European segment, historically absent from the Group's revenue base, now contributes through multiple newly established and acquired entities. The disclosed terms indicate that ABCnow consolidation commences from Q2FY27 and that Canadian commercial revenues remain pending further approvals, introducing execution dependency on these newer geographies.
Sector / Market Context
India's pharmaceutical exports exceeded USD 27 billion in FY26 according to Pharmaceuticals Export Promotion Council data, with the US, UK, and European markets remaining the dominant destinations. Consolidation of front-end presence in European markets through subsidiary structures has become an increasing focus for mid-sized Indian generic exporters seeking to reduce distributor dependence and improve per-unit realisations.